{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:12:08Z","timestamp":1785946328485,"version":"3.56.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["1833073"],"award-info":[{"award-number":["1833073"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["CO-2018-12365521"],"award-info":[{"award-number":["CO-2018-12365521"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The advent of biologic drugs revolutionised the treatment of many chronic inflammatory diseases in rheumatology, dermatology, and gastroenterology. The introduction of different targeted agents closely followed the increase in knowledge of pathogenic mechanisms. The identification of IL-23 as a master regulator of \u2018pathogenic\u2019 inflammation and the consequent efficacy of IL-23 blocking agents were first proofed in psoriasis and then in other inflammatory diseases such as psoriatic arthritis and Crohn\u2019s disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed all available results from anti-Il-23 clinical trials for psoriasis, focusing on data of IBDologists\u2019 interest. Regarding guselkumab, we analysed data from phase III clinical trials VOYAGE1, VOYAGE2, and NAVIGATE. For risankizumab, we reported efficacy and safety results from UltIMMa-1, UltIMMa-2, and IMMvent clinical trials, and tildrakizumab was evaluated by analysing data from reSURFACE1 and reSURFACE2 studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from all the clinical trials that we reported showed both the efficacy of all three anti-IL-23 drugs in psoriasis and the safety of this class; in particular, no gastrointestinal side effects were observed in those studies. IL-23 blockers have shown promising short- and long-term results in psoriasis, with a major safety profile and no negative interactions with gastrointestinal system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-IL-23 indication for psoriatic arthritis is very recent and for IBD is still to come. Therefore, dermatologists are accumulating long-term experience with these drugs, both in clinical trials and in real-world evidence, which can help gastroenterologists in the management of IBD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac023","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:11:15Z","timestamp":1644523875000},"page":"ii20-ii29","source":"Crossref","is-referenced-by-count":23,"title":["What Can IBD Specialists Learn from IL-23 Trials in Dermatology?"],"prefix":"10.1093","volume":"16","author":[{"given":"Mario","family":"Valenti","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy"},{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pavia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy"},{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy"},{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy"},{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"2022051214010623600_CIT0001","doi-asserted-by":"crossref","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2022051214010623600_CIT0002","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"key":"2022051214010623600_CIT0003","doi-asserted-by":"crossref","first-page":"774808","DOI":"10.3389\/fphar.2021.774808","article-title":"Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis","volume":"12","author":"Cai","year":"2021","journal-title":"Front Pharmacol"},{"key":"2022051214010623600_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2021.1899112","article-title":"Effects of TNF-\u03b1 inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients","author":"Narcisi","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2022051214010623600_CIT0005","first-page":"89","article-title":"Adherence to topical treatment can improve treatment-resistant moderate psoriasis","volume":"105","author":"Okwundu","year":"2020","journal-title":"Cutis"},{"key":"2022051214010623600_CIT0006","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0007","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"2022051214010623600_CIT0008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomised, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2022051214010623600_CIT0009","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomised trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2022051214010623600_CIT0010","doi-asserted-by":"crossref","first-page":"e005091","DOI":"10.1136\/bmjopen-2014-005091","article-title":"Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: trial design and protocol [CONSTRUCT]","volume":"4","author":"Seagrove","year":"2014","journal-title":"BMJ Open"},{"key":"2022051214010623600_CIT0011","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2022051214010623600_CIT0012","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2022051214010623600_CIT0013","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomised trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"2022051214010623600_CIT0014","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022051214010623600_CIT0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"J Gastroenterol"},{"key":"2022051214010623600_CIT0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"2022051214010623600_CIT0017","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"2022051214010623600_CIT0018","article-title":"Consensus on the place in therapy of biologics in the treatment of patients with chronic plaque psoriasis","author":"Burlando","year":"2021","journal-title":"Italy J Dermatol Venerol"},{"key":"2022051214010623600_CIT0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0020","author":"European Medicines Agency","year":"2017"},{"key":"2022051214010623600_CIT0021","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab [an IL-23-specific mAb] demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2022051214010623600_CIT0022","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/ijms11030789","article-title":"Interleukin 12 a key immunoregulatory cytokine in infection applications","volume":"11","author":"Hamza","year":"2010","journal-title":"Int J Mol Sci"},{"key":"2022051214010623600_CIT0023","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","article-title":"Guselkumab: a review in moderate to severe plaque psoriasis","volume":"19","author":"Al-Salama","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2022051214010623600_CIT0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2022051214010623600_CIT0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomised withdrawal and re-treatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2022051214010623600_CIT0026","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomised, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0027","article-title":"Consistency of response [PASI-90 or 100 and IGA 0 or 0\/1] in patients with moderate to severe psoriasis treated with guselkumab: results from the VOYAGE 1 and 2 trials [poster 6894]","author":"Gordon","year":"2018;  ,"},{"key":"2022051214010623600_CIT0028","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis [ECLIPSE]: results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2022051214010623600_CIT0029","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"UNCOVER-1 Study Group; UNCOVER-2 Study Group. UNCOVER-3 Study Group Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2022051214010623600_CIT0030","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17-mediated immunity to the opportunistic fungal pathogen candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J Immunol"},{"key":"2022051214010623600_CIT0031","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomised, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2022051214010623600_CIT0032","author":"European Medicines Agency","year":"2019"},{"key":"2022051214010623600_CIT0033","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051214010623600_CIT0034","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/ijd.15008","article-title":"Complicated coronavirus disease 2019 [COVID-19] in a psoriatic patient treated with ixekizumab","volume":"59","author":"Facheris","year":"2020","journal-title":"Int J Dermatol"},{"key":"2022051214010623600_CIT0035","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis [UltIMMa-1 and UltIMMa-2]: results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2022051214010623600_CIT0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/PTT.S165943","article-title":"Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date","volume":"8","author":"Machado","year":"2018","journal-title":"Psoriasis"},{"key":"2022051214010623600_CIT0037","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis [IMMvent]: a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2022051214010623600_CIT0038","doi-asserted-by":"crossref","first-page":"adv00605","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2022051214010623600_CIT0039","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","article-title":"Tildrakizumab: a review in moderate-to-severe plaque psoriasis","volume":"20","author":"Frampton","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2022051214010623600_CIT0040","author":"European Medicines Agency","year":"2019"},{"key":"2022051214010623600_CIT0041","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab [MK-3222], an antiinterleukin- 23p19 monoclonal antibody, improves psoriasis in a phase IIb randomised placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis [reSURFACE 1 and reSURFACE 2]: results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2022051214010623600_CIT0043","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomised controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0044","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase III clinical trials [reSURFACE 1 and reSURFACE 2] through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13671-018-0216-y","article-title":"IL-23 inhibitors for psoriasis","volume":"7","author":"Beck","year":"2018","journal-title":"Curr Dermatol Rep"},{"key":"2022051214010623600_CIT0046","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjd.17918","article-title":"Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0047","first-page":"e15228","article-title":"Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study","author":"Narcisi","year":"2021","journal-title":"Dermatol Ther"},{"key":"2022051214010623600_CIT0048","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"2022051214010623600_CIT0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population","author":"Valenti","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2022051214010623600_CIT0050","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T cell profiles within psoriatic skin during treatment with guselkumab vs secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2022051214010623600_CIT0051","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"key":"2022051214010623600_CIT0052","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.14113","article-title":"IL-15 and IL-23 synergize to trigger Th17 response by CLA+ T cells in psoriasis","volume":"29","author":"de Jes\u00fas-Gil","year":"2020","journal-title":"Exp Dermatol"},{"key":"2022051214010623600_CIT0053","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.3390\/jcm10173822","article-title":"Skin-resident memory T cells: pathogenesis and implication for the treatment of psoriasis","volume":"10","author":"Vu","year":"2021","journal-title":"J Clin Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii20\/43679578\/jjac023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii20\/43679578\/jjac023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T14:07:40Z","timestamp":1652364460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/Supplement_2\/ii20\/6584455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":53,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,5,11]]},"published-print":{"date-parts":[[2022,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac023","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,4,1]]}}}